We read with great interest the results from the GOLD study,1 which compared olaparib plus paclitaxel with placebo plus paclitaxel as second-line therapy for patients with advanced gastric cancer in a double-blind, randomised phase 3 setting. Despite the negative result, some aspects of the study warrant closer attention in comparison with the previous phase 2 trial (Study 39; NCT01063517), which showed a positive finding.
http://ift.tt/2E4XRPA
Τετάρτη 31 Ιανουαρίου 2018
[Correspondence] Use of olaparib in patients with advanced gastric cancer
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου